Lausanne, Switzerland, July 19, 2018 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company focused on neurodegenerative diseases, today announced the price per common share of USD 11.75 for the offerings of up to 10 million new common shares of the Company. The offering price will be the same for all three offerings, the details of which were published yesterday, namely: The first subscription rights offering; The primary offering; and The second subscription rights offering. An aggregate of 7,391,305 shares were sold in the first subscription rights offering and primary offering. The Company expects gross proceeds from the offerings, before deducting the...
|
